The Food and Drug Administration has cleared a Richland company's GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer.
IsoRay said it will allow doctors to treat more brain cancer patients than previously possible with conventional ways to deliver radiation.
The system also is less likely to damage healthy brain tissue than other methods, according to IsoRay.
With the FDA clearance, IsoRay will move forward in seeking additional regulatory approval for its new liquid form of Cesium-131 internal radiation therapy for the treatment of brain cancer that would be delivered using the GliaSite system.
Before IsoRay acquired the GliaSite technology, approximately 500 GliaSite cases were performed annually at some 40 hospitals worldwide.